BR0306809A - Sistema terapêutico para o tratamento de tumores, método de tratamento de um tumor, e, uso de uma combinação de um anticorpo radiomarcado e um agente quimioterapêutico - Google Patents

Sistema terapêutico para o tratamento de tumores, método de tratamento de um tumor, e, uso de uma combinação de um anticorpo radiomarcado e um agente quimioterapêutico

Info

Publication number
BR0306809A
BR0306809A BR0306809-9A BR0306809A BR0306809A BR 0306809 A BR0306809 A BR 0306809A BR 0306809 A BR0306809 A BR 0306809A BR 0306809 A BR0306809 A BR 0306809A
Authority
BR
Brazil
Prior art keywords
chemotherapeutic agent
combination
treatment
therapeutic system
tumor
Prior art date
Application number
BR0306809-9A
Other languages
English (en)
Inventor
Gail Rowlinson-Busza
Original Assignee
Antisoma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Plc filed Critical Antisoma Plc
Publication of BR0306809A publication Critical patent/BR0306809A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

"SISTEMA TERAPêUTICO PARA O TRATAMENTO DE TUMORES, MéTODO DE TRATAMENTO DE UM TUMOR, E, USO DE UMA COMBINAçãO DE UM ANTICORPO RADIOMARCADO E UM AGENTE QUIMIOTERAPêUTICO". A invenção refere-se a um sistema terapêutico compreendendo (i) um anticorpo radiomarcado, que se liga seletivamente em mucina epitelial polimórfica (PEM) tal como o anticorpo monoclonal HMPG-1, e (ii) um agente quimioterapêutico, tal como Taxotere<32>. O anticorpo radiomarcado e o agente quimioterapêutico são administrados em combinação um com o outro para produzir um efeito terapêutico sinérgico.
BR0306809-9A 2002-01-12 2003-01-13 Sistema terapêutico para o tratamento de tumores, método de tratamento de um tumor, e, uso de uma combinação de um anticorpo radiomarcado e um agente quimioterapêutico BR0306809A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0200657.5A GB0200657D0 (en) 2002-01-12 2002-01-12 Cancer treatment
PCT/GB2003/000105 WO2003057250A1 (en) 2002-01-12 2003-01-13 Cancer treatment

Publications (1)

Publication Number Publication Date
BR0306809A true BR0306809A (pt) 2004-12-07

Family

ID=9928970

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306809-9A BR0306809A (pt) 2002-01-12 2003-01-13 Sistema terapêutico para o tratamento de tumores, método de tratamento de um tumor, e, uso de uma combinação de um anticorpo radiomarcado e um agente quimioterapêutico

Country Status (16)

Country Link
US (1) US20050163707A1 (pt)
EP (1) EP1465661A1 (pt)
JP (1) JP2005520802A (pt)
KR (1) KR20040091623A (pt)
CN (1) CN1638797A (pt)
AU (1) AU2003205813A1 (pt)
BR (1) BR0306809A (pt)
CA (1) CA2472893A1 (pt)
GB (2) GB0200657D0 (pt)
IL (1) IL162814A0 (pt)
MX (1) MXPA04006747A (pt)
NO (1) NO20042850L (pt)
PL (1) PL371419A1 (pt)
RU (1) RU2004124520A (pt)
WO (1) WO2003057250A1 (pt)
ZA (1) ZA200405414B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting

Also Published As

Publication number Publication date
GB0300600D0 (en) 2003-02-12
AU2003205813A1 (en) 2003-07-24
RU2004124520A (ru) 2005-03-20
IL162814A0 (en) 2005-11-20
GB2383538B (en) 2003-11-19
CN1638797A (zh) 2005-07-13
GB0200657D0 (en) 2002-02-27
WO2003057250A1 (en) 2003-07-17
KR20040091623A (ko) 2004-10-28
US20050163707A1 (en) 2005-07-28
JP2005520802A (ja) 2005-07-14
MXPA04006747A (es) 2006-01-30
CA2472893A1 (en) 2003-07-17
PL371419A1 (en) 2005-06-13
NO20042850L (no) 2004-08-26
GB2383538A (en) 2003-07-02
EP1465661A1 (en) 2004-10-13
ZA200405414B (en) 2005-06-22

Similar Documents

Publication Publication Date Title
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
PT1472541E (pt) Agentes de imagiologia e métodos de imagiologia de naaladase de psma
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
BRPI0513866A (pt) composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
BR0210057A (pt) Composição compreendendo agentes antifúngicos para tratar vulvovaginite e vaginose
TR201910145T4 (tr) Tümörlerin tedavi edilmesine yönelik anti-CD38 artı kortikosteroidler artı bir kortikosteroid-olmayan kemoterapötik.
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR9807418A (pt) Terapia de gene supressor de tumor combinado e quimioterapia no tratamento de neoplasmas
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE509630T1 (de) Pankreaskrebsbehandlung mit na+/k+-atpase-hemmern
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BRPI0409588A (pt) composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]